NCT00379015View on ClinicalTrials.gov

Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Breast Cancer
Interventions
BIOLOGICAL

trastuzumab

DRUG

cyclophosphamide

DRUG

docetaxel

DRUG

epirubicin hydrochloride

PROCEDURE

conventional surgery

PROCEDURE

neoadjuvant therapy

Trial Locations (5)

791-0288

Shikoku Cancer Center, Matsuyama

811-1395

National Kyushu Cancer Center, Fukuoka

160-8582

Keio University Hospital, Tokyo

173-8605

Teikyo University School of Medicine, Tokyo

951-8566

Niigata Cancer Center Hospital, Niigata

All Listed Sponsors
lead

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

OTHER

NCT00379015 - Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter